Safety of eye drops for wet age-related macular degeneration

This is an early-stage safety study of CG-P5 peptide eye drops, a new treatment being tested for wet age-related macular degeneration—a serious eye condition that damages the macula, the part of the eye responsible for sharp, central vision. Researchers will compare the medication to a placebo (inactive eye drops) and to Eylea, a standard treatment that is injected into the eye. The goal is to understand whether the new eye drops are safe and how well patients tolerate them.

Wet macular degeneration causes progressive vision loss and significantly impacts quality of life. Current treatments require injections directly into the eye, which can be uncomfortable and inconvenient. This trial is exploring whether eye drops—a simpler, non-invasive way to deliver medication—could be a safer and more tolerable option for patients.